Lv3
400 积分 2025-01-20 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
16小时前
待确认
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
16小时前
已完结
Development of Chinese innovative drugs in the USA
3天前
已完结
From Challenges to Solutions: A Review of Fourth-Generation EGFR Tyrosine Kinase Inhibitors to Overcome the C797S Triple Mutation in Non-Small Cell Lung Cancer
19天前
已完结
Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)
25天前
已完结
Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial
28天前
已完结
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
1个月前
已完结
Mapping the effectiveness and risks of GLP-1 receptor agonists
1个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
皖公网安备34019202002308
